Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B Mn7XRZBweHSxc3nzJGF{e2G7 NWjTV4dXOeLCk{ZCpO69VQ>? MUm0PEBp MlXmbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MUGyOlMzQTZyOB?=
PLC/PRF/5  MV3BdI9xfG:|aYOgRZN{[Xl? NVewT4NROeLCk{ZCpO69VQ>? NVmwWlh3PDhiaB?= M3TheIlvcGmkaYTzJINmdGxiZ4Lve5Rp MXmyOlMzQTZyOB?=
HepG2  M4j5dWFxd3C2b4Ppd{BCe3OjeR?= MoXzNgKBmzYEoN88US=> MUe0PEBp M3;GR4lvcGmkaYTzJINmdGxiZ4Lve5Rp M{D6S|I3OzJ7NkC4
HEK293 MWTGeY5kfGmxbjDBd5NigQ>? NWHucpdIOC534pEJ{txO MkDrNk81NzZiaB?= M3rHeJJm\HWlZYOgS3JRPzhiZYjwdoV{e2mxbh?= NX\lXJRGOjV6NUiwN|I>
GEO NGr6eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ENE4xOS1{MDFOwG0> M4r2blk3KGh? M{\TO2ROW09? NYDVSFlwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnnQNlU5Ozh|OUG=
SW48 NUXLc5FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXruXm5IOC5yMT2yNEDPxE1? MkS1PVYhcA>? NHy4Z|JFVVOR MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYLIPYl3OjV6M{izPVE>
HT29 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWyNE4xOS1{MDFOwG0> NVW1UldFQTZiaB?= MmS0SG1UVw>? MkXBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3KweFI2QDN6M{mx
SW480 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jOV|AvODFvMkCg{txO Mk[2PVYhcA>? M1LVcGROW09? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkHUNlU5Ozh|OUG=
SW620 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vNE4xOS1{MDFOwG0> M37GU|k3KGh? NE\S[pRFVVOR MnTlbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4XuPFI2QDN6M{mx
HCT116 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVywMlAyNTJyIN88US=> NVfUfZJvQTZiaB?= M1S5[WROW09? NYLCTWhvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3HTe|I2QDN6M{mx
LOVO M{nTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ENE4xOS1{MDFOwG0> M{S1b|k3KGh? NFPpUWpFVVOR NYOydHpycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF2yV4kzPTh|OEO5NS=>
HCT150 M2fXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\pd4R{OC5yMT2yNEDPxE1? M33ud|k3KGh? MkXnSG1UVw>? MkPRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2i3SFI2QDN6M{mx
SW48-CR MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrh[5M6OC5yMT2yNEDPxE1? NF3OSGE6PiCq MYXEUXNQ MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWCyOVg{QDN7MR?=
GEO-CR MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjsTpB5OC5yMT2yNEDPxE1? NUKwbnJvQTZiaB?= MXPEUXNQ MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXTKT3FyOjV6M{izPVE>
KB-31 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\pfGlEPTB;NT61xtExNjNibl2= NXvueItUOjV5NUOzOlE>
KB-G2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W2SmlEPTB;OT6xxtExNjFibl2= NYG5XnZpOjV5NUOzOlE>
LLC-PK1 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR{LkFCtVMvOiCwTR?= NG\hVYozPTd3M{O2NS=>
LLC-PK1/MRP2 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqxNIM1UUN3ME24Nk41yrF{Lkegcm0> MYGyOVc2OzN4MR?=
HEK293 NVT2eIc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q4VmlEPTB;MUGuNOKyOS5{IH7N MUGyOVc2OzN4MR?=
HEK293/OATP1B1 NIjxPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jCcWlEPTB;Nj6yxtExNjNibl2= NG\FfnMzPTd3M{O2NS=>
HROC18 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XNNmlEPTB;MT6zJO69VQ>? Mm\uNlU{ODl7MUS=
HROC24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV32RWM6UUN3ME20MlYh|ryP MVGyOVMxQTlzNB?=
HROC43 NWTwU29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojxTWM2OD13LkOg{txO Mo[3NlU{ODl7MUS=
HROC46 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGzcoVKSzVyPUKuOEDPxE1? Mo\WNlU{ODl7MUS=
RJ345 NUnPVmZQTnWwY4Tpc44hSXO|YYm= NXTBWItSOC53L{Wg{txO M{\qRlI1KGh? NUPnPI1PTE2VTx?= NIj5SIpqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> MkfINlUzPTN7OUS=
RJ348 NYmxRox2TnWwY4Tpc44hSXO|YYm= NVG2To0yOC53L{Wg{txO M1j3TFI1KGh? MXfEUXNQ MXXpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= M1K1TVI2OjV|OUm0
MCF-7 MXXGeY5kfGmxbjDBd5NigQ>? M4fTZ|AvPS93IN88US=> NUfNcYlbOjRiaB?= NVfTUHhCTE2VTx?= NGmyTGtqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NHfXPXAzPTJ3M{m5OC=>
MDA-MB-231 NI\KdmxHfW6ldHnvckBCe3OjeR?= NVHMRndGOC53L{Wg{txO M123bVI1KGh? M3PBO2ROW09? NYW3fohUcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v NWHMdWZuOjV{NUO5PVQ>
HT15 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf1N45DOS1{MDFOwG0> MYi0PEBp Ml:4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGrmV4QzPTB5MUCxPC=>
DLD1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XIZlEuOjBizszN NEPrZlk1QCCq MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWCyOVA4OTBzOB?=
HT-29 NV;sWVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXuOW8yNTJyIN88US=> NFe4fmw1QCCq M1faUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4L6elI2ODdzMEG4
Hct-116 M3frfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3ENU0zOCEQvF2= MkH3OFghcA>? NGH3RmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MViyOVA4OTBzOB?=
HT15 NFLnOpRCeG:ydH;zbZMhSXO|YYm= MoCwNU0yOCEQvF2= NFG4e|Y1QCCq M{j3Solv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVfKUJRIOjVyN{GwNVg>
DLD1 NXrTSGVVSXCxcITvd4l{KEG|c3H5 NWjiXYN1OS1zMDFOwG0> MXO0PEBp M2\FR4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnHkNlUxPzFyMUi=
HT-29 MUXBdI9xfG:|aYOgRZN{[Xl? MlrnNU0yOCEQvF2= MXW0PEBp NEnaTIlqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{nud|I2ODdzMEG4
Hct-116 MnzpRZBweHSxc3nzJGF{e2G7 M2C5PFEuOTBizszN NF7nUYc1QCCq NF\Xd2ZqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVj6c|hROjVyN{GwNVg>
GBM5 MVXBdI9xfG:|aYOgRZN{[Xl? M{DEVlAvPeLCk{GuNQKBkc7:TR?= M37PTVI1KGh? NUHrcolnTE2VTx?= MkLDbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo MYOyOFkyOTJzNR?=
GBM6 NEKxU2pCeG:ydH;zbZMhSXO|YYm= NGTEVI4xNjYkgKOxMlDjiIoQvF2= NEmxbYozPCCq Mn\uSG1UVw>? Mlj1bY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo MUCyOFkyOTJzNR?=
GBM12 MYHBdI9xfG:|aYOgRZN{[Xl? MoW2NE426oDVMT6w5qCK|ryP MXeyOEBp NGPPcFFFVVOR NGPIdZdqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> NWDkT2pKOjR7MUGyNVU>
GBM14  MXjBdI9xfG:|aYOgRZN{[Xl? NXPCOVFnOC534pETNU4x6oDLzszN NF7TZlUzPCCq NVu0cJl4TE2VTx?= MVjpcpRmemGldIOge4l1cCCuYYDheIlvcWJidH:gbY5lfWOnIHPlcIwh\GWjdHi= Ml;PNlQ6OTF{MUW=
Hep3B MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;EUVIy6oDVMj61xsDPxE1? M1nkblI1NzR6L{eyJIg> MlH0bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NWnIO3R6OjR6OEW4PVA>
PLC/PRF/5  NHfEN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT2bWoy6oDVMj61xsDPxE1? NEfN[3ozPC92OD:3NkBp NVjQXYR1cW6qaXLpeJMh[2WubDDndo94fGh? MmnwNlQ5QDV6OUC=
HepG2  MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XQVFHjiJN{LkZCpO69VQ>? NYHSWJNlOjRxNEivO|IhcA>? MU\pcohq[mm2czDj[YxtKGe{b4f0bC=> NVHqfWNpOjR6OEW4PVA>
HCT116  M{DlPGZ2dmO2aX;uJGF{e2G7 M{DH[VExNzJyL{SwJO69VQ>? M3TFZlI1KGh? MVrpcoR2[2W|IGDVUWEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NYTJUndnOjR5NkO2NVE>
Lim2405 NIjjNJlHfW6ldHnvckBCe3OjeR?= M3nuTFQxKM7:TR?= NUnGNpRTOjRiaB?= Mmn4bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MV[yOFc3OzZzMR?=
LoVo M3TYVWZ2dmO2aX;uJGF{e2G7 Mn\COFAh|ryP MX6yOEBp MVrpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MWeyOFc3OzZzMR?=
Lim1215 M3PnbWZ2dmO2aX;uJGF{e2G7 MYe0NEDPxE1? M2q3XlI1KGh? MVnpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> Ml;JNlQ4PjN4MUG=
SW48 NILYRYdHfW6ldHnvckBCe3OjeR?= MWC0NEDPxE1? NH7hWmYzPCCq NWjQR4REcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NH;V[I4zPDd4M{[xNS=>
RKO  NVH3[nhkTnWwY4Tpc44hSXO|YYm= MYi0NEDPxE1? M{nyUFI1KGh? NYLrO3dPcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NH7PVWUzPDd4M{[xNS=>
SW837 NF;nZ4VHfW6ldHnvckBCe3OjeR?= M3TQSlQxKM7:TR?= NVG4SFlxOjRiaB?= MWLpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M{jXZ|I1PzZ|NkGx
SW1463 NV\JbIdjTnWwY4Tpc44hSXO|YYm= MXu0NEDPxE1? NGP4NpkzPCCq M1OxOIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NVe1cpNIOjR5NkO2NVE>
SW480 NIW1c3hHfW6ldHnvckBCe3OjeR?= MnLwOFAh|ryP Mny5NlQhcA>? NIHlU5JqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MmXJNlQ4PjN4MUG=
Vaco432 MkD5SpVv[3Srb36gRZN{[Xl? MUO0NEDPxE1? M4rGZlI1KGh? MnWxbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MmLJNlQ4PjN4MUG=
Vaco400 NX20W45jTnWwY4Tpc44hSXO|YYm= NH3aXos1OCEQvF2= MnrBNlQhcA>? M3PvbYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M3exPVI1PzZ|NkGx
DLD1 M{TheWZ2dmO2aX;uJGF{e2G7 MXu0NEDPxE1? NYXTT|IzOjRiaB?= NYrlZ5N7cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MlzaNlQ4PjN4MUG=
HT29  MmDLSpVv[3Srb36gRZN{[Xl? M4LwOFQxKM7:TR?= Mn\4NlQhcA>? M360fYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M4DIclI1PzZ|NkGx
PLC/PRF/5  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2foW|HjiJN3wsXN NVS0UoFpOjRxNEivO|IhcA>? MVHpcohq[mm2czDj[YxtKGe{b4f0bC=> NH;nemUzOzF4OUG0PC=>
HepG2 NFLKRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrCUoV[OeLCk{ZCuW0> MlW4NlQwPDhxN{KgbC=> MmDmbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3T4eVI{OTZ7MUS4
Hep3B  NF3ROHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnPe5ky6oDVNdM1US=> MliyNlQwPDhxN{KgbC=> MofibY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnjMNlMyPjlzNEi=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID